Literature DB >> 24052438

Applicability of gene expression profile of childhood acute lymphoblastic leukemia at diagnosis and at the end of the induction phase of chemotherapy at a cancer hospital in the state of Goiás (Brazil).

Lysa B Minasi1, Fernanda R Godoy, Daniela de M e Silva, Thaís C Vieira, Cláudio C da Silva, Aparecido D da Cruz.   

Abstract

The present study compared the gene expression pattern of some previously described genes at the time of diagnosis and after induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) in patients submitted to Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 Protocol. Samples were obtained at the time of diagnosis from 16 patients with ALL and on the 28th day of induction chemotherapy the bone marrow samples were obtained from 12 children. The genes expression profiles in diagnostic and induction samples were analyzed by array-based qPCR and then related to the clinical and biological prognostic factors. The results showed significant associations (p ≤ 0.05) between gender and immunophenotype, immunophenotype and age, immunophenotype and risk group, presence of CD10 and RUNX1 expression, risk group, and immunophenotype. A significant positive correlation was observed between the expression levels of BAX and BCL2. There was a significant difference (p = 0.008) between the gene expression pattern at the time of diagnosis and after induction chemotherapy. The expression pattern of these genes after the induction phase of treatment approached the expression profile of the control group, indicating a good induction response in children treated according to the GBTLI ALL-99 protocol. The findings of the current research could be routinely useful for clinical practice and could assist in the discovery phase of medical applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24052438     DOI: 10.1007/s13277-013-1192-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

1.  Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).

Authors:  R Consolini; A Legitimo; R Rondelli; C Guguelmi; E Barisone; A Lippi; A Cantù-Rajnoldi; M Aricò; V Conter; M G Cocito; M C Putti; A Pession; G Masera; A Biondi; G Basso
Journal:  Haematologica       Date:  1998-11       Impact factor: 9.941

2.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

3.  Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.

Authors:  Silvia R Brandalise; Vitória R Pinheiro; Simone S Aguiar; Eduardo I Matsuda; Rosemary Otubo; José A Yunes; Waldir V Pereira; Eny G Carvalho; Lilian M Cristofani; Marcelo S Souza; Maria L Lee; Jane A Dobbin; Maria S Pombo-de-Oliveira; Luiz F Lopes; Katharina N T Melnikoff; Algemir L Brunetto; Luiz G Tone; Carlos A Scrideli; Vera L L Morais; Marcos B Viana
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 4.  Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance.

Authors:  Carlos Graux
Journal:  Transfus Apher Sci       Date:  2011-02-25       Impact factor: 1.764

5.  Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia.

Authors:  L A Hogarth; A G Hall
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  Immunophenotyping of leukemia.

Authors:  D Campana; F G Behm
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

7.  AML1 gene over-expression in childhood acute lymphoblastic leukemia.

Authors:  F M Mikhail; K A Serry; N Hatem; Z I Mourad; H M Farawela; D M El Kaffash; L Coignet; G Nucifora
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

8.  Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.

Authors:  Anita Peter; Thomas Heiden; Tillmann Taube; Gabriele Körner; Karl Seeger
Journal:  Eur J Haematol       Date:  2009-07-06       Impact factor: 2.997

9.  CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome.

Authors:  Nadia Dakka; Hicham Bellaoui; Nadia Bouzid; Mohammed Khattab; Youssef Bakri; Abdelaziz Benjouad
Journal:  Pediatr Hematol Oncol       Date:  2009-06       Impact factor: 1.969

10.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.